Fertin Sustainability Profile
Fertin, officially known as Fertin Pharma A/S, is a leading player in the pharmaceutical and healthcare industry, headquartered in Denmark (DK). Founded in 2006, the company has established itself as a pioneer in the development of innovative oral delivery systems, particularly in the field of nicotine replacement therapy and other consumer health products. With a strong presence in Europe and North America, Fertin focuses on creating unique solutions that enhance the efficacy and user experience of medicinal products. Their core offerings include advanced chewing gum and lozenge formulations, which are distinguished by their high bioavailability and consumer-friendly designs. Fertin's commitment to quality and innovation has positioned it as a trusted partner for global brands, earning recognition for its contributions to the industry and its ability to adapt to evolving market demands.
DitchCarbon Score
How does Fertin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fertin's score of 63 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fertin's reported carbon emissions
In 2024, Fertin Pharma A/S reported total carbon emissions of approximately 36,673,000 kg CO2e across all scopes. This includes 3,654,000 kg CO2e from Scope 1, 1,538,000 kg CO2e from Scope 2 (market-based), and a significant 36,673,000 kg CO2e from Scope 3 emissions. The total emissions from Scope 1 and 2 combined amounted to about 5,192,000 kg CO2e. In 2023, Fertin's emissions were slightly lower, with total emissions of about 34,261,000 kg CO2e, comprising 4,742,000 kg CO2e from Scope 1, 1,865,000 kg CO2e from Scope 2 (market-based), and 34,261,000 kg CO2e from Scope 3. The combined Scope 1 and 2 emissions for that year were approximately 6,607,000 kg CO2e. Fertin Pharma's emissions data is cascaded from its parent company, Philip Morris International Inc., reflecting a corporate family relationship. However, there are currently no specific reduction targets or climate pledges disclosed by Fertin, indicating a potential area for future commitment and improvement in their sustainability strategy. Overall, Fertin Pharma's emissions profile highlights the significant impact of Scope 3 emissions, which typically encompass the majority of a company's carbon footprint, particularly in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | - | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 |
How Carbon Intensive is Fertin's Industry?
How Carbon Intensive is Fertin's Location?
Fertin's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Fertin has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
